NCT05601232View on ClinicalTrials.gov

A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

August 31, 2025

Conditions
Unresectable Angiosarcoma
Interventions
RADIATION

BNCT

Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.

Trial Locations (1)

Unknown

National Cancer Center Hospital, Tokyo

All Listed Sponsors
collaborator

Cancer Intelligence Care Systems, Inc.

INDUSTRY

lead

Stella Pharma Corporation

INDUSTRY